Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

Treatment with decitabine resulted in a similar survival and fewer adverse...

Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany

Treatment with decitabine resulted in a similar survival and fewer adverse events compared with chemo in older patients with AML ( Prof Michael Lübbert - Universitätsklinikum Freiburg, Freiburg, Germany )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

ASCO 2022: Panel discussion on bladder preservation

Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller

ASCO 2022: Panel discussion on bladder preservation ( Dr Petros Grivas, Prof Rob Jones, Prof Phil Cornford and Prof Kurt Miller )

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer...

Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San...

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients ( Dr Virginia G. Kaklamani - UT Health San Antonio MD Anderson Cancer Center, San Antonio, USA )

ASCO 2022: Latest in prostate cancer, including PARP inhibitors

Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford

ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild...

Dr Chiara Cremolini - University of Pisa, Pisa, Italy

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC ( Dr Chiara Cremolini - University of Pisa, Pisa, Italy )

Dabrafenib plus trametinib significantly increases overall response rate in...

Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada

Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Eric Bouffet - The Hospital for Sick Children, Toronto, Canada )

Comment: Dabrafenib plus trametinib significantly increases overall response...

Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA

Comment: Dabrafenib plus trametinib significantly increases overall response rate in paediatric low-grade gliomas ( Dr Melissa Hudson- St. Jude Children's Research Hospital, Memphis, USA )

ASCO 2022: Latest developments in mHSPC and mCRPC

Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller

ASCO 2022: Latest developments in mHSPC and mCRPC ( Prof Heather Payne, Prof Kim Chi, Prof Laura-Maria Krabbe and Prof Kurt Miller )

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

More from ecancer